General American Investors’s Applied DNA Sciences Inc Warrant APDNW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-281,409
Closed -$1K 81
2019
Q3
$1K Hold
281,409
﹤0.01% 68
2019
Q2
$3K Hold
281,409
﹤0.01% 69
2019
Q1
$5K Hold
281,409
﹤0.01% 66
2018
Q4
$1K Hold
281,409
﹤0.01% 68
2018
Q3
$73K Hold
281,409
0.01% 68
2018
Q2
$79K Hold
281,409
0.01% 69
2018
Q1
$75K Hold
281,409
0.01% 68
2017
Q4
$101K Hold
281,409
0.01% 68
2017
Q3
$197K Hold
281,409
0.02% 61
2017
Q2
$113K Hold
281,409
0.01% 58
2017
Q1
$114K Hold
281,409
0.01% 61
2016
Q4
$141K Hold
281,409
0.01% 65
2016
Q3
$317K Hold
281,409
0.03% 61
2016
Q2
$322K Hold
281,409
0.03% 56
2016
Q1
$511K Hold
281,409
0.05% 53
2015
Q4
$472K Sell
281,409
-578,591
-67% -$1.47M 0.04% 56
2015
Q3
$2.58M Hold
860,000
0.23% 56
2015
Q2
$1.2M Hold
860,000
0.1% 59
2015
Q1
$903K Buy
860,000
+210,000
+32% +$286K 0.07% 59
2014
Q4
$787K Buy
+650,000
New +$643K 0.06% 60

General American Investors's APDNW Position: Q4 2019 in Review

General American Investors sold out of Applied DNA Sciences Inc Warrant (APDNW) in Q4 2019, closing a stake of 281,409 shares — an estimated $1K sold.

General American Investors first reported a position in APDNW in Q4 2014 and held it in 20 quarters. The position peaked at $2.58M in Q3 2015. 0 funds tracked by Wall St. Rank hold APDNW as of Q4 2019.

  • General American Investors reported no remaining Applied DNA Sciences Inc Warrant position as of Q4 2019 after selling out during the quarter.
  • General American Investors sold 281,409 Applied DNA Sciences Inc Warrant shares in Q4 2019, an estimated $1K.
  • General American Investors first reported a position in Applied DNA Sciences Inc Warrant in Q4 2014 and held it in 20 quarters.
  • General American Investors's Applied DNA Sciences Inc Warrant position peaked at $2.58M in Q3 2015.
  • 0 funds tracked by Wall St. Rank held Applied DNA Sciences Inc Warrant as of Q4 2019.

Based on General American Investors's 13F filing for Q4 2019, filed 20 Feb 2020.